Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Department of Psychology, University of South Florida, Tampa, FL, USA.
Leuk Lymphoma. 2023 Feb;64(2):415-423. doi: 10.1080/10428194.2022.2148208. Epub 2022 Dec 7.
This controlled comparison study evaluated objective and subjective cognitive function and their relationships with patient-reported symptoms (depression, fatigue, insomnia) in patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and non-cancer controls. Patients with CML in chronic phase treated with the same oral TKI for ≥6 months ( = 90) and non-cancer controls ( = 87) completed a neurocognitive battery and self-report measures. Patients demonstrated worse overall neuropsychological performance = .05) and verbal memory ( = .02) compared to controls. Patients were not more likely to meet criteria for impaired cognitive performance compared to controls (>.26). Patients reported worse subjective global and domain-specific cognitive complaints and less satisfaction with cognitive function compared to controls (s < .05). Patients also reported greater fatigue and insomnia symptoms (s < .001). In both groups, greater fatigue, insomnia, and depressive symptoms were associated with worse subjective cognition (s < .01). Longitudinal studies are needed to examine changes in cognitive function in patients before and during TKI treatment.
这项对照研究评估了接受酪氨酸激酶抑制剂（TKI）治疗的慢性髓性白血病（CML）患者和非癌症对照者的客观和主观认知功能及其与患者报告的症状（抑郁、疲劳、失眠）的关系。慢性期接受相同口服 TKI 治疗≥6 个月的 CML 患者（n=90）和非癌症对照者（n=87）完成了神经认知测试和自我报告量表。与对照组相比，患者的整体神经心理表现（p=0.05）和言语记忆（p=0.02）更差。与对照组相比，患者不太可能符合认知功能受损的标准（p>0.26）。与对照组相比，患者报告的主观整体和特定领域的认知主诉更差，对认知功能的满意度更低（p<0.05）。患者还报告了更多的疲劳和失眠症状（p<0.001）。在这两个组中，疲劳、失眠和抑郁症状越严重，主观认知越差（p<0.01）。需要进行纵向研究来检查 TKI 治疗前和治疗期间患者认知功能的变化。
